Shigeyuki Toyoizumi

6PUBLICATIONS
35CO-AUTHORS
Regenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsOther Asian languages (excl. South-East Asian)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 21, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka

|Dec 31, 2024
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.

Nobuaki Matsubara, Hideaki Miyake, Hiroji Uemura

|Jul 17, 2024
Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry.

Masayoshi Harigai, Eiichi Tanaka, Eisuke Inoue

|Jul 30, 2022
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.

Haruru Kotani, Norikazu Masuda, Toshinari Yamashita

|Jun 23, 2022
Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.

Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim

|Jun 23, 2021
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.

Yoichi Naito, Yasutoshi Kuboki, Masafumi Ikeda

Pageof 1

Frequent Collaborators

3 joint publications

Yuko Mori

3 joint publications

Natsuki Hori

2 joint publications

Yoichi Naito

2 joint publications

Nobuaki Matsubara